Comment on serum urate-lowering efficacy and safety of Tigulixostat in gout patients with hyperuricemia: A randomized, double-blind, placebo-controlled, dose-finding trial

Int J Rheum Dis. 2024 Jan;27(1):e15024. doi: 10.1111/1756-185X.15024.

Authors

Tai-Ming Hsu¹, Hui Wen Chang¹, Ai-Lin Chen², James Cheng-Chung Wei^{3

4

5}

Affiliations

¹ School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
² School of Medical Science and Technology, Chung Shan Medical University, Taichung, Taiwan.
³ Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
⁴ Department of Allergy, Immunology, and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
⁵ Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

PMID: 38287554
DOI: 10.1111/1756-185X.15024

No abstract available

Publication types

Randomized Controlled Trial
Letter

MeSH terms

Double-Blind Method
Gout Suppressants / adverse effects
Gout* / diagnosis
Gout* / drug therapy
Humans
Hyperuricemia* / diagnosis
Hyperuricemia* / drug therapy
Uric Acid

Substances

Gout Suppressants
Uric Acid